Anfield Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Anfield Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2	Closed	-$1.93K	–	511
2024 Q1	$1.93K	Buy	+2	New	+$1.9K	﹤0.01%	253
2023 Q1	–	Sell	-228	Closed	-$165K	–	89
2022 Q4	$165K	Sell	228 -229	-50%	-$169K	0.08%	67
2022 Q3	$315K	Buy	457 +16	+4%	+$10.1K	0.15%	64
2022 Q2	$261K	Buy	441 +64	+17%	+$41.6K	0.12%	67
2022 Q1	$263K	Buy	377 +196	+108%	+$124K	0.1%	70
2021 Q4	$114K	Buy	181 +165	+1,031%	+$101K	0.04%	78
2021 Q3	$10K	Sell	16 -2	-11%	-$1.24K	﹤0.01%	94
2021 Q2	$10K	Buy	+18	New	+$9.12K	﹤0.01%	167

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Anfield Capital Management's REGN Position: Q2 2024 in Review

Anfield Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 2 shares — an estimated $1.93K sold.

Anfield Capital Management first reported a position in REGN in Q2 2021 and held it in 8 quarters. The position peaked at $315K in Q3 2022. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

Anfield Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Anfield Capital Management sold 2 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $1.93K.
Anfield Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 8 quarters.
Anfield Capital Management's Regeneron Pharmaceuticals position peaked at $315K in Q3 2022.
1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Anfield Capital Management's 13F filing for Q2 2024, filed 31 Jul 2024.